Circulating immune complexes in patients with lung cancer.

Lowe, J B; Segal‐Eiras, Amada; Iles, P.B.; Baldwin, Robert

doi:10.1136/thx.36.1.56

Cited by 9 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite many efforts made during the past decades, a suitable biochemical and/or immunochemical marker has not yet been found. Recently, more attention has been given to circulating immune complexes and their constituent antigens in lung-cancer patients in a search for lungcancer markers (Garcia et a[., 1987;Bukh et al, 1988;Lowe et a/., 1981;Baseler et a/., 1987;Paluch and Ioachim, 1978;Havemann et a[., 1979;Guy et a[., 1981;Day et al, 1981). Despite convincing evidence by a variety of techniques that immune complexes are present in the sera of lung-cancer patients, relatively few reports have detailed the biochemical characteristics of the antigenic components in these complexes.…”

Section: Discussionmentioning

confidence: 99%

“…1975). Elevated levels of immune complexes are also associated with several types of human cancers, including melanoma (Jerry et al, 1976), GI malignancy (Ristow et a/., 1979), Hodgkin's disease (Bepler et al, 1985), and breast (Krieger et al, 1983) and lung cancer (Garcia et al, 1987;Bukh eral., 1988;Lowe et al, 1981). Circulating immune complexes have been found, by a variety of techniques, in the sera of patients with cancer, and levels have tended generally to correlate with stage of disease in most series (Ruiz-Arguelles et a/., 1982;Theofilopoulos et al, 1977).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Characterization of a lung‐cancer‐associated auto‐antigen

Zeng

Alpert

1992

Intl Journal of Cancer

View full text Add to dashboard Cite

An antigen, protein X (Px), was purified from immune complexes isolated from malignant pleural effusions from patients with adenocarcinoma of the lung by EDTA treatment, PEG 8000 precipitation, protein A affinity chromatography, and Sephadex G-200 separation in the presence of 3 M NaCl. The purified antigen had a M(r) 17,000 by SDS-PAGE, and consisted of isoelectric species of pI 6.3 and 6.6. Purified Px recombined with Ig isolated from pleural fluids from patients with lung adenocarcinoma, but not with Ig from patients with breast carcinoma. Using an autologous human and heterologous chicken antibody, Px was found, by immunohistology, in the cytoplasm of some of the well-differentiated lung adenocarcinoma cells, but was not seen in normal lung or a variety of other malignant tissues. A liquid-phase competitive-inhibition RIA was developed. Over 30 ng/ml of Px were found in 9 of 15 pleural fluids from patients with lung carcinoma, none of 20 from patients with breast, ovary, stomach or colon cancer, and in 3 of 15 patients with unknown primary tumor. Our data suggest that Px may be a lung-cancer-associated autoantigen which can elicit a host humoral response in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Characterization of a lung‐cancer‐associated auto‐antigen

Zeng

Alpert

1992

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The present investigation reports studies in patients with osteogenic sarcoma and related bone tumours, to determine the frequency of elevated CIC levels in comparison with related studies in carcinoma of breast, lung and colon (Hoffien et al, 1977;Baldwin et al, 1979a;Lowe et al, 1980;Vellacott et al, 1980) since it has previously been reported that osteogenic sarcomas express neoantigens which induce humoral immune responses (Byers et al, 1975;Byers and Johnston, 1977).…”

mentioning

confidence: 89%

Circulating immune complexes in patients with bone tumours

Eiras

Robins

Baldwin

et al. 1980

Intl Journal of Cancer

View full text Add to dashboard Cite

Sera from 62 patients with osteogenic sarcoma and 12 with malignant giant-cell tumour were tested for the presence of immune complexes by the 125I-Clq binding assay. Elevated serum Clq binding activity was found in 67.7% of the osteogenic sarcoma patients and in 75% of the giant-cell tumour patients. These results were compared with those obtained with five sera from patients with benign bone tumours and 20 sera from normal young donors. In the last two groups, the incidence of elevated Clq-binding activity was 0% and 5%, respectively. In some patients with giant-cell tumours, pre- and post-operative serum samples were studied, showing a decrease in test values after tumour resection. Preliminary sequential studies of individual patients indicate that the 125I-Clq binding assay may be useful for monitoring patients with bone tumours.

show abstract

“…TuMouR-associated antigens may be released from developing tumours and result in the formation of immune complexes in serum or other body fluids (I). Elevated serum levels of circulating immune complexes have been detected in many different malignancies (2)(3)(4)(5), and Rossen et al recorded the highest levels in patients who had residual tumour after surgical treatment and in those with rapidly progressing malignant disease (6). The measurement of immune com lexes in the circulation may, therefore, be useful in the gagnosis and prognosis of malignant disease.…”

mentioning

confidence: 99%

Circulating immune complexes in patients with benign and malignant colorectal tumours

Vellacott

Baldwin

Balfour

et al. 1981

British Journal of Surgery

Self Cite

View full text Add to dashboard Cite

Circulating immune complexes were measured using a modified Clq binding assay in 100 preoperative patients with colorectal cancer and in 52 patients with benign polyps. Sixty-one per cent of the patients with cancer and 49 per cent of the patients with benign polyps had elevated levels, as did 92 per cent of those with malignant polyps. There was no relation to a, the stage of the disease, with 10 out of 13 Dukes' A tumours (77 per cent) having increased levels; b, the degree of differentiation of the cancers; c, the tumour mass. However, cancers on the right side of the colon had significantly higher levels than rectal cancers.

show abstract

Circulating immune complexes in patients with lung cancer.

Cited by 9 publications

References 9 publications

Characterization of a lung‐cancer‐associated auto‐antigen

Characterization of a lung‐cancer‐associated auto‐antigen

Circulating immune complexes in patients with bone tumours

Circulating immune complexes in patients with benign and malignant colorectal tumours

Contact Info

Product

Resources

About